JCM
CRL icon

Junto Capital Management’s Charles River Laboratories CRL Stock Holding History

Junto Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-99,867
Closed -$15.2M – 82
2025
Q2 		$15.2M Buy
+99,867
New +$13.3M 0.32% 70

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Junto Capital Management's CRL Position: Q3 2025 in Review

Junto Capital Management sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 99,867 shares — an estimated $15.2M sold.

Junto Capital Management first reported a position in CRL in Q2 2025 and held it in 1 quarter. The position peaked at $15.2M in Q2 2025. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Junto Capital Management reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
  • Junto Capital Management sold 99,867 Charles River Laboratories shares in Q3 2025, an estimated $15.2M.
  • Junto Capital Management first reported a position in Charles River Laboratories in Q2 2025 and held it in 1 quarter.
  • Junto Capital Management's Charles River Laboratories position peaked at $15.2M in Q2 2025.
  • 556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Junto Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.